RARE
Ultragenyx Pharmaceutical Inc
Price:  
42.55 
USD
Volume:  
606,783.00
United States | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

RARE EV/EBITDA

-391.2%
Upside

As of 2024-07-22, the EV/EBITDA ratio of Ultragenyx Pharmaceutical Inc (RARE) is -6.25. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RARE's latest enterprise value is 3,867.88 mil USD. RARE's TTM EBITDA according to its financial statements is -619.22 mil USD. Dividing these 2 quantities gives us the above RARE EV/EBITDA ratio.

Note: valuation result may not be accurate due to the company's negative EBITDA.

Range Selected
Trailing P/E multiples 13.2x - 17.8x 14.5x
Forward P/E multiples 20.7x - 24.6x 23.3x
Fair Price (135.57) - (116.63) (123.92)
Upside -418.6% - -374.1% -391.2%
42.55 USD
Stock Price
(123.92) USD
Fair Price

RARE EV/EBITDA - Historical EV/EBITDA Data

Date EV/EBITDA
2024-07-19 -6.25
2024-07-18 -6.28
2024-07-17 -6.45
2024-07-16 -6.66
2024-07-15 -6.53
2024-07-12 -6.64
2024-07-11 -6.45
2024-07-10 -6.23
2024-07-09 -6.20
2024-07-08 -6.09
2024-07-05 -5.99
2024-07-03 -5.89
2024-07-02 -6.01
2024-07-01 -6.03
2024-06-28 -6.03
2024-06-27 -6.08
2024-06-26 -5.94
2024-06-25 -5.84
2024-06-24 -5.77
2024-06-21 -5.80
2024-06-20 -5.56
2024-06-18 -5.47
2024-06-17 -5.83
2024-06-14 -5.72
2024-06-13 -6.33
2024-06-12 -6.56
2024-06-11 -6.07
2024-06-10 -6.16
2024-06-07 -6.07
2024-06-06 -6.13
2024-06-05 -6.08
2024-06-04 -6.00
2024-06-03 -6.03
2024-05-31 -5.88
2024-05-30 -5.66
2024-05-29 -5.58
2024-05-28 -5.76
2024-05-24 -5.91
2024-05-23 -5.85
2024-05-22 -6.02
2024-05-21 -5.95
2024-05-20 -6.09
2024-05-17 -6.14
2024-05-16 -6.26
2024-05-15 -6.03
2024-05-14 -6.01
2024-05-13 -6.01
2024-05-10 -6.00
2024-05-09 -6.05
2024-05-08 -6.10